JPRN-UMIN000000902已完成1 期
Immunotherapy Using HLA-A24-restricted Survivin-derived Peptide for Patients with Colorectal Cancer and Breast Cancer - Phase I Clinical Study of Survivin-2B Peptide Vaccine Therapy
Department of Surgery, Sapporo Medical University School of Medicine0 个研究点目标入组 30 人开始时间: 2007年11月23日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Exclusion criteria included (1) the presence of other cancers that might influence the prognosis, (2) immunodeficiency or a history of splenectomy, (3) need of steroid therapy, (4) severe cardiac insufficiency, acute infection, or hematopoietic failure, (5) prior cancer therapy such as chemotherapy, radiation therapy, steroid therapy, or other immunotherapy within the past 4 weeks, (6) ongoing breast-feeding, and (7) unsuitability for the trial based on clinical judgment.
研究者
相似试验
已完成
1 期
Immunotherapy Using HLA-A24-restricted Survivin-derived Peptide Combined with IFA and IFN-alpha for Patients with Urothelial Cancer (Phase I clinical study)JPRN-UMIN000005859Department of Urology, Sapporo Medical University School of Medicine15
未知
1 期
Immunotherapy Using HLA-A24-restricted Survivin-derived Peptide Mixed with IFA, IFA and IFN-alpha, IFA and IL-2, or IFA and GM-CSF for Patients with Digestive Cancer and Endocrine Organic Cancer (Phase I clinical study)Advanced or recurrent digestive cancer and Endocrine Organic CancerJPRN-UMIN000000905Department of Surgery, Sapporo Medical University School of Medicine108
已完成
1 期
Immunotherapy Using HLA-A24-restricted Survivin-derived Peptide for Patients with Urothelial Cancer (Phase I clinical study)Advanced or recurrent urothelial cancerJPRN-UMIN000001499Department of Urology, Sapporo Medical University School of Medicine12
已完成
1 期
Immunotherapy Using HLA-A24-restricted Survivin-derived Peptide for Patients with Oral CancerAdvanced or recurrent oral cancerJPRN-UMIN000000976Department of Oral Surgery, Sapporo Medical University School of Medicine10
已完成
1 期
Immunotherapy Using HLA-A24-restricted Survivin-derived Peptide Mixed with IFA and IFN-alpha for Patients with Oral Cancer (Phase I clinical study)Advanced or recurrent oral cancerJPRN-UMIN000000999Department of Oral Surgery, Sapporo Medical University School of Medicine7